NCT00431210View on ClinicalTrials.gov

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2015

Study Completion Date

January 26, 2016

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

Epstein-Barr virus-specific adoptive T-cells immunotherapy

Given intravenously on Day 1 and Day 14

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00431210 - Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter